Search Press releases Keywords From To 27 Sep 2024 UCB announces late-breaking two-year data for BIMZELX[®]▼(bimekizumab) in moderate to severe hidradenitis suppurativa at EADV 2024 Read More 26 Sep 2024 Transparency notification BlackRock, Inc. Read More 25 Sep 2024 Transparency notification BlackRock, Inc. Read More 25 Sep 2024 UCB presents new 4-year data for BIMZELX[®]▼(bimekizumab) in moderate to severe plaque psoriasis at EADV 2024 Read More 24 Sep 2024 Transparency notification BlackRock, Inc. Read More 24 Sep 2024 UCB and Biogen Announce Positive Topline Results From Phase 3 Study of Dapirolizumab Pegol in Systemic Lupus Erythematosus and are Initiating Second Phase 3 Study in 2024 Read More Pagination First page Previous page Previous … Page 17 Page 18 Page 19 Page 20 Current page 21 Page 22 Page 23 Page 24 Page 25 … Page 21 of 67 Next page Next Last page Stay up-to-date on the latest news and information from UCB Subscribe
